Daiichi Sankyo files for approval of silodosin in China
Japanese drugmaker Daiichi Sankyo has filed an application for KMD-3213 (silodosin) to China's State Food and Drug Administration (SFDA). The agent is a selective alpha 1A-adrenoceptor antagonist developed for the treatment of dysuria associated with benign prostatic hyperplasia. Originally discovered by fellow Japanese firm Kissei Pharmaceutical, it was developed together with Daiichi and is jointly marketed as Urief in Japan. KMD-3213 has shown efficacy in significantly improving urinary disturbance soon after dosage.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze